Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary goal of this study is to compare a new symptoms rating questionnaire, called the Vancouver Semi-Structured Interview for Depression (V-SID), to the traditionally used questionnaires. The investigators predict that the V-SID will be more sensitive to patients' improvement than are traditional questionnaires.
Depression is sometimes associated with difficulties in thinking skills. Recent evidence suggests that in those people who have thinking difficulties, effective treatment and improvement of depression can also result in improved thinking skills. Therefore, a test of thinking skills is included in this study.
This study will also evaluate three other potential indicators of treatment response: cortisol, cytokines, and grip strength.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment-as-usual | All patients will receive treatment as usual: antidepressant medication and/or cognitive behavioral therapy (CBT). Patients' results will be compare to their own baseline measurements. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Treatment-as-usual | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hamilton Rating Scale for Depression (HAM-D) | Pre-Baseline, Day 0, Week 1, Week 4, Week 8 | |
| Vancouver Semi-Structured Interview for Depression (V-SID) | Pre-Baseline, Day 0, Week 1, Week 4, Week 8 | |
| Montgomery-Asberg Depression Rating Scale (MADRS) | Pre-Baseline, Day 0, Week 1, Week 4, Week 8 | |
| Clinical Global Impression | Pre-Baseline, Day 0, Week 1, Week 4, Week 8, Followup | |
| Hamilton Rating Scale for Anxiety (HAM-A) | Pre-Baseline, Day 0, Week 1, Week 4, Week 8 | |
| British Columbia Major Depression Inventory (BC-MDI) | Pre-Baseline, Day 0, Week 1, Week 4, Week 8 | |
| Quality of Life Enjoyment Satisfaction Questionnaire (Q-LES-Q) | Day 0, Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| CNS Vital Signs | Pre-Baseline, Day 0, Week 8 | |
| British Columbia Cognitive Complaints Inventory (BC-CCI) | Pre-Baseline, Day 0, Week 1, Week 4, Week 8 | |
| Grip strength |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
All subjects will diagnosed with a current major depressive episode. They will be recruited from a community healthcare centre.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Diane McIntosh, MD, FRCPC | Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Copeman Neuroscience Centre | Vancouver | British Columbia | V6Z 2L4 | Canada |
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma and white blood cells will be isolated from whole blood samples and will be stored for future analysis.
| Pre-Baseline, Day 0, Week 8 |
| Cortisol level | Day 0, Week 8 |
| Neuroimmunobiologic markers | Pre-Baseline, Week 8 |
| Evaluation for Metabolic Syndrome | Day 0, Week 8, Followup |